Drug Trial Radar · NCT07809919
A First-in-human, Safety, Tolerability, and Pharmacokinetics Study of LXE408 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
88
Actual
Start
Dec 21, 2018
Primary completion
Sep 27, 2021
Study completion Sep 27, 2021
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Sep 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this first-in-human study is to generate the necessary safety, tolerability, and pharmacokinetics (PK) information that will support further clinical development of LXE408 for the treatment of patients with visceral leishmaniasis and potentially Chagas disease.
Conditions
- Visceral Leishmaniasis
- Chagas Disease
Interventions
LXE408Drug
LXE408 comes in film coated tablets and is taken orally.
PlaceboDrug
LXE408 matching placebo comes in film coated tablets and is taken orally.
IohexolDrug
Iohexol is a nonionic, water-soluble radiographic contrast medium with a molecular weight of 821.14 and is administered to the participant via intravenous (IV) injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Parts A & B: Number of participants with Adverse Events, physical exam findings, vital signs, ECG findings, safety laboratory assessments including chemistry, hematology, and urinalysis resultsTime frame: Part A: Single Ascending Dose (SAD): 35 days; Part A: SAD (Food Effect): 63 days; Part B: Multiple Ascending Dose (MAD): 45 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Vince and Associates PA and Vince and Associates Inc
Overland Park, Kansas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.